For treatment of pancreatic or gastrointestinal NETs, somatostatin may be used when the tumor size is small and disease progression is slow, molecular-targeted agents should be selected when the tumor size is medium, and cytotoxic agents including STZ are preferred when the tumor size is bulky and disease progression is fast (23,24). The gene discussed is SST; the disease is neoplasm.